[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100500772":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":49,"collaborators":20,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":20,"enrollmentInfo":60,"targetDuration":20,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":20,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Fox Chase Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Venofer treatment","EXPERIMENTAL","Venofer (iron-sucrose) 200mg (5 days) every week administered as an IV infusion",[13],"Drug: Venofer",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Venofer","Intravenous iron will be administered as five doses of 200 mg of iron sucrose (Venofer, American Regent, Shirley, NJ) in 100 ml normal saline over a duration of 15 minutes to 1 hour",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Iberia Sosa, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Ryan Romasko","CONTACT","2678388380","ryan.romasko@fccc.edu",[32],{"facility":5,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Philadelphia","Pennsylvania","19111","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-75.16362,39.95238,{"lat":43,"lon":42},[46,48],{"name":27,"role":28,"phone":47,"phoneExt":20,"email":30},"267-838-8380",{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":50,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100500772","phase-2-iron-replacement-to-reduce-anemia-during-neoadjuvant-chemotherapy-100500772",false,"NCT05800600","Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy","Iron-RANC","Inclusion Criteria:\n\n* Male or female patients \\> 18 years\n* Patients undergoing neoadjuvant chemotherapy, including radiation and\u002For immunotherapy, with intent for curative surgical resection for breast, thoracic, gastrointestinal (GI) or genitourinary (GU) malignancies.\n* Anemia defined as Hgb \\\u003C10.5 g\u002FdL during chemotherapy.\n* Iron storage levels of ferritin \\\u003C500 ng\u002FmL and iron saturation \\\u003C35%\n* Ability to understand and willingness to sign a written informed consent and HIPAA consent document\n\nExclusion Criteria:\n\n* Diagnosis of anemia at the time of cycle 1 day 1 of neoadjuvant chemotherapy, Hgb \\\u003C 11.0 g\u002FdL, uncontrolled intercurrent illness including, but not limited to, ongoing active infection, symptomatic new\u002Fexacerbated congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Prior parenteral iron infusion in the past 4 weeks\n* The use of erythropoietin stimulating agents within 4 weeks unless chronic needs due to CKD\n* Concurrent systemic infection at the time of enrollment.\n* Known hypersensitivity to Iron sucrose\n* Pregnant or breast feeding. Refer to section 4.4 for further detail.\n* Anemia from another established etiology (i.e MDS, Myeloma)","ALL","18 Years",{"count":61,"type":62},34,"ESTIMATED","INTERVENTIONAL",[65],"PHASE2","This is an open-label, single institution study evaluating the efficacy of intravenous iron sucrose monotherapy in patients with thoracic, breast, GU and GI malignancies undergoing neoadjuvant chemotherapy with the goal of undergoing surgical resection.",[68],"Anemia","2026-05-20",{"date":71,"type":72},"2026-05-22","ACTUAL",{"date":74,"type":72},"2023-03-15",{"date":76,"type":62},"2028-02-01",{"name":5,"class":6},1]